CN107108753A - C1酯酶抑制剂融合蛋白及其用途 - Google Patents

C1酯酶抑制剂融合蛋白及其用途 Download PDF

Info

Publication number
CN107108753A
CN107108753A CN201580067942.4A CN201580067942A CN107108753A CN 107108753 A CN107108753 A CN 107108753A CN 201580067942 A CN201580067942 A CN 201580067942A CN 107108753 A CN107108753 A CN 107108753A
Authority
CN
China
Prior art keywords
fusion protein
days
seq
human
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580067942.4A
Other languages
English (en)
Chinese (zh)
Inventor
A·诺顿
C·潘
A·伊斯肯德瑞安
B·斯特拉克-罗格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Shire Human Genetics Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Human Genetics Therapies Inc filed Critical Shire Human Genetics Therapies Inc
Priority to CN202110936129.3A priority Critical patent/CN113698495B/zh
Publication of CN107108753A publication Critical patent/CN107108753A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
CN201580067942.4A 2014-10-31 2015-10-31 C1酯酶抑制剂融合蛋白及其用途 Pending CN107108753A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110936129.3A CN113698495B (zh) 2014-10-31 2015-10-31 C1酯酶抑制剂融合蛋白及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462073657P 2014-10-31 2014-10-31
US62/073,657 2014-10-31
PCT/US2015/058521 WO2016070156A2 (en) 2014-10-31 2015-10-31 C1 esterase inhibitor fusion proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110936129.3A Division CN113698495B (zh) 2014-10-31 2015-10-31 C1酯酶抑制剂融合蛋白及其用途

Publications (1)

Publication Number Publication Date
CN107108753A true CN107108753A (zh) 2017-08-29

Family

ID=54548264

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110936129.3A Active CN113698495B (zh) 2014-10-31 2015-10-31 C1酯酶抑制剂融合蛋白及其用途
CN201580067942.4A Pending CN107108753A (zh) 2014-10-31 2015-10-31 C1酯酶抑制剂融合蛋白及其用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202110936129.3A Active CN113698495B (zh) 2014-10-31 2015-10-31 C1酯酶抑制剂融合蛋白及其用途

Country Status (10)

Country Link
US (1) US20160130324A1 (enExample)
EP (2) EP3769780A1 (enExample)
JP (3) JP6740225B2 (enExample)
KR (2) KR20240035643A (enExample)
CN (2) CN113698495B (enExample)
AU (2) AU2015338913B2 (enExample)
BR (1) BR112017008962A2 (enExample)
CA (1) CA2964132A1 (enExample)
MA (1) MA53991A (enExample)
WO (1) WO2016070156A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114207135A (zh) * 2019-06-11 2022-03-18 夏尔人类遗传性治疗公司 用于治疗由失调的血浆激肽释放酶介导的疾病的抗体的腺相关病毒载体递送

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018010160A8 (pt) * 2015-11-19 2019-02-26 Shire Human Genetic Therapies inibidor da c1 esterase humana recombinante e usos do mesmo
WO2018037046A1 (en) 2016-08-23 2018-03-01 Csl Behring Gmbh Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
AU2018281337B2 (en) 2017-06-06 2022-08-25 Relinia, Inc. Single-chain TNF receptor 2 agonist fusion proteins
US20210393794A1 (en) * 2017-06-20 2021-12-23 Sichuan Baili Pharm Co.Ltd Screening of fixed-point coupling sites of cysteine-modified antibody-toxin conjugate (tdc)
EP3866860B1 (en) * 2018-10-15 2025-01-08 The Regents Of The University Of California Complement component 1s (c1s) deficient cells for production of vaccines and biopharmaceutical proteins
CN111087475B (zh) * 2019-12-25 2022-07-08 东莞市东阳光生物药研发有限公司 Fgf21融合蛋白及抑制其降解的方法
CN113493519B (zh) * 2020-03-19 2022-12-27 浙江道尔生物科技有限公司 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白
WO2022109124A1 (en) 2020-11-20 2022-05-27 Csl Behring Gmbh Method for treating antibody-mediated rejection
WO2025072726A1 (en) 2023-09-29 2025-04-03 Trex Bio, Inc. Tnf-alpha variant fusion molecules

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011116291A1 (en) * 2010-03-18 2011-09-22 Thrombolytic Science International Production of human c1 inhibitor in human cells
CN103476795A (zh) * 2011-03-29 2013-12-25 罗切格利卡特公司 抗体Fc 变体
CN104080474A (zh) * 2011-12-22 2014-10-01 德国杰特贝林生物制品有限公司 C1-抑制剂在治疗中枢神经系统继发性水肿中的应用
WO2014173873A1 (en) * 2013-04-22 2014-10-30 Csl Behring Gmbh Complex

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US5149636A (en) 1982-03-15 1992-09-22 Trustees Of Columbia University In The City Of New York Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
FR2672895B1 (fr) 1991-02-15 1995-05-12 Transgene Sa Procede de purification d'une proteine fortement glycosylee.
WO1992022320A1 (en) * 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
CN1406249B (zh) * 2000-02-11 2010-06-16 默克专利股份有限公司 增加基于抗体的融合蛋白的循环半衰期
AU2001261024A1 (en) * 2000-04-12 2001-10-30 Delta Biotechnology Limited Albumin fusion proteins
ES2649037T3 (es) * 2000-12-12 2018-01-09 Medimmune, Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
AU2003249055B2 (en) 2002-07-15 2008-06-26 Immunex Corporation Methods and media for controlling sialylation of proteins produced by mammalian cells
US8524477B2 (en) 2002-10-29 2013-09-03 Crucell Holland B.V. Methods to obtain recombinant proteins with increased sialylation from cells that express adenovirus E1A protein, and proteins obtained thereby
US7384754B2 (en) 2003-10-31 2008-06-10 Agilent Technologies, Inc. Enrichment and tagging of glycosylated proteins
MX2007001424A (es) * 2004-08-03 2008-03-13 Biorexis Pharmaceutical Corp Terapia de combinacion usando proteinas de fusion a transferrina que comprenden peptido 1 tipo glucagon.
GB0507123D0 (en) 2005-04-08 2005-05-11 Isis Innovation Method
ES2523666T3 (es) 2005-05-31 2014-11-28 Board Of Regents, The University Of Texas System Anticuerpos IgG1 con la parte Fc mutada para el aumento de unión al receptor FcRn y usos de los mismos
WO2007070315A2 (en) 2005-12-08 2007-06-21 Amgen Inc. Improved production of glycoproteins using manganese
EP2623610B1 (en) 2006-02-10 2015-04-29 Life Technologies Corporation Labeling and detection of post translationally modified proteins
JP5570809B2 (ja) 2006-09-01 2014-08-13 ノボ ノルディスク ヘルス ケア アーゲー 修飾タンパク質
IL182956A0 (en) 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
EP2195444B9 (en) 2007-10-12 2015-09-16 Sigma-Aldrich Co. LLC Cell line and methods for improved glycoprotein sialylation
RU2495131C2 (ru) 2008-02-19 2013-10-10 Байокон Лимитид Способ получения рекомбинантного инсулина гларгина
EP2166085A1 (en) 2008-07-16 2010-03-24 Suomen Punainen Risti Veripalvelu Divalent modified cells
CN102317309A (zh) 2009-02-26 2012-01-11 巴特勒能源同盟有限公司 通过不同的翻译后修饰改变和调节蛋白质活性
JP2013511281A (ja) 2009-11-23 2013-04-04 アムジェン インコーポレイテッド 単量体抗体Ｆｃ
WO2011108714A1 (ja) * 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
US20120010013A1 (en) * 2010-06-19 2012-01-12 Fellows Edwin E Swing assistant device
AU2011288412A1 (en) 2010-08-13 2013-02-21 Medimmune Limited Monomeric polypeptides comprising variant Fc regions and methods of use
JP6147670B2 (ja) * 2010-12-22 2017-06-14 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 改善された半減期を有する修飾された抗体
CA2826337A1 (en) 2011-02-10 2012-08-16 Manfred Wuhrer Method for the purification of a glycan and/or a glycoconjugate by chromatography using a stationary phase comprising cotton
US8580922B2 (en) 2011-03-04 2013-11-12 Shire Human Genetic Therapies, Inc. Peptide linkers for polypeptide compositions and methods for using same
CA2839619C (en) * 2011-06-28 2021-11-16 Inhibrx Llc Serpin fusion polypeptides and methods of use thereof
BR112014000352A2 (pt) 2011-07-08 2017-02-14 Merck Sharp & Dohe Corp método de purificar uma proteína de fusão-fc, proteínas de fusão contendo fc purificada, tnfr:fc purificada, e tnfr:fc elevadamente purificada
CN102890790B (zh) * 2011-07-22 2014-04-30 鸿富锦精密工业（深圳）有限公司 扩展卡
AU2012340501A1 (en) 2011-12-19 2013-07-11 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
EP2623110A1 (en) * 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
US9676857B2 (en) 2012-03-16 2017-06-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Soluble engineered monomeric Fc
US10233229B2 (en) 2012-12-07 2019-03-19 Pfizer Inc. Engineered monomeric antibody fragments
AU2014224599B2 (en) * 2013-03-08 2018-11-08 Csl Behring Gmbh Treatment and prevention of remote ischemia-reperfusion injury
US20160184458A1 (en) * 2013-03-14 2016-06-30 Shire Human Genetic Therapies, Inc. Mrna therapeutic compositions and use to treat diseases and disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011116291A1 (en) * 2010-03-18 2011-09-22 Thrombolytic Science International Production of human c1 inhibitor in human cells
CN103476795A (zh) * 2011-03-29 2013-12-25 罗切格利卡特公司 抗体Fc 变体
CN104080474A (zh) * 2011-12-22 2014-10-01 德国杰特贝林生物制品有限公司 C1-抑制剂在治疗中枢神经系统继发性水肿中的应用
WO2014173873A1 (en) * 2013-04-22 2014-10-30 Csl Behring Gmbh Complex

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MARIA COUTINHO等: "Functional Analysis of the Serpin Domain of C1 Inhibitor", 《THE JOURNAL OF IMMUNOLOGY》 *
TIMO RATH等: "Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics", 《CRITICAL REVIEWS IN BIOTECHNOLOGY》 *
何玉池等: "《细胞生物学》", 31 August 2014 *
吕世静等: "《临床免疫学检验》", 31 August 2015 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114207135A (zh) * 2019-06-11 2022-03-18 夏尔人类遗传性治疗公司 用于治疗由失调的血浆激肽释放酶介导的疾病的抗体的腺相关病毒载体递送

Also Published As

Publication number Publication date
KR102753264B1 (ko) 2025-01-10
KR20240035643A (ko) 2024-03-15
US20160130324A1 (en) 2016-05-12
AU2015338913A1 (en) 2017-05-04
EP3212663A2 (en) 2017-09-06
CN113698495B (zh) 2025-06-06
KR20170074244A (ko) 2017-06-29
EP3769780A1 (en) 2021-01-27
JP2018503355A (ja) 2018-02-08
CN113698495A (zh) 2021-11-26
JP2023027290A (ja) 2023-03-01
JP6740225B2 (ja) 2020-08-12
AU2015338913B2 (en) 2020-11-19
BR112017008962A2 (pt) 2018-01-16
WO2016070156A3 (en) 2016-06-23
JP2020202841A (ja) 2020-12-24
MA53991A (fr) 2021-09-15
EP3212663B1 (en) 2020-05-27
CA2964132A1 (en) 2016-05-06
HK1243443A1 (en) 2018-07-13
WO2016070156A2 (en) 2016-05-06
AU2021200977A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
JP2023027290A (ja) Ｃ１エステラーゼ阻害因子融合タンパク質及びその使用
CN102655877B (zh) Fgf21突变体及其用途
JP7562747B2 (ja) 組換えヒトｃ１エステラーゼインヒビター及びその使用
TWI513705B (zh) 纖維母細胞生長因子２１蛋白質
JP2019047828A (ja) 一本鎖Ｆｃ融合タンパク質
JP2022000053A (ja) Ｘｔｅｎを有するトロンビン切断可能リンカー及びその使用
US10167329B2 (en) Stabilized insulin-like growth factor polypeptides
EP3672621A1 (en) Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
CA3251039A1 (en) NEW CD200 FUSION PROTEINS
HK40045832A (en) C1 esterase inhibitor fusion proteins and uses thereof
HK1243443B (en) C1 esterase inhibitor fusion proteins and uses thereof
US20210355187A1 (en) Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20210716

Address after: Osaka, Japan

Applicant after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Massachusetts, USA

Applicant before: SHIRE HUMAN GENETIC THERAPIES, Inc.

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170829